Enterprise value to EBIT forward of Pulmonx Corp. – LSX:A2P1AF
This article focuses on the "Enterprise value to EBIT forward" metric for Pulmonx Corp. (LSX:A2P1AF). It appears to be a financial data snippet from TradingView, providing an overview of a specific valuation ratio for the company's stock. The content points to financial data available on the platform, indicating market and company-specific information.
Price to earnings forward of Pulmonx Corp. – LSX:A2P1AF
This article provides the "Price to earnings forward" valuation metric for Pulmonx Corp. (LSX:A2P1AF). It indicates the value and change of this financial data point over a period. The information is presented within the context of TradingView's platform, which offers various financial tools and market data services.
Price to earnings forward of Pulmonx Corp. – DUS:4NI
This article provides the "Price to earnings forward" data for Pulmonx Corp. (DUS:4NI) on the TradingView platform. It details the company's financial information, presented within the context of the Düsseldorf Stock Exchange. The content is primarily a data page on a financial platform rather than an analytical article.
Price to sales forward of Pulmonx Corp. – DUS:4NI
This page from TradingView provides financial information for Pulmonx Corp. (4NI) listed on the Dusseldorf Stock Exchange, specifically focusing on its forward price-to-sales ratio. The article includes standard market data and copyright information, indicating that the market for this stock is currently closed with no recent trades.
Pulmonx Corp highlights its respiratory device portfolio as investors assess long-term growth prospects
Pulmonx Corp (PULM) focuses on developing minimally invasive medical devices for severe emphysema and other chronic obstructive pulmonary diseases, targeting a significant unmet medical need. The company's business model involves selling specialized devices to healthcare providers and supporting their usage with training. Investors evaluate Pulmonx's prospects based on its ability to expand device adoption, enter new markets, and maintain regulatory and reimbursement support.
Pulmonx Corp. Actuals & Estimates (NASDAQ:LUNG)
This article provides financial actuals and estimates for Pulmonx Corporation (NASDAQ: LUNG), including its current stock price, historical performance, analyst forecasts, and company financials. It details the company's market capitalization, last quarter's earnings and revenue, and upcoming earnings report date. The company does not pay dividends and has 296 employees.
Pulmonx Corp (LUNG) Financial Health: Profitability & Balance Sheet Analysis
Pulmonx Corp (LUNG) has a stable financial status but low operating efficiency, ranking 142 out of 204 in the Healthcare Equipment & Supplies industry with a financial score of 6.69. The company's latest quarterly revenue decreased by 8.66% year-over-year to $20.59 million, and its net profit saw a 5.50% year-over-year decline. Key financial metrics related to cash, assets, revenue, and profit are mentioned, though specific details beyond quarterly figures are noted as not yet disclosed.
Pulmonx Corp (LUNG) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Pulmonx Corp (LUNG), highlighting its price momentum score of 5.32 within the Healthcare Equipment & Supplies industry. It details the stock's current trading range between a resistance level of $1.59 and a support level of $1.09, suggesting suitability for range-bound swing trading. The analysis also includes aggregated technical indicators, predominantly signaling a "Sell" based on moving averages.
Pulmonx Corp (LUNG) Institutional Confidence
Pulmonx Corp (LUNG) has an institutional shareholding score of 7.00, placing it 79th out of 204 in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion increased by 10.02% quarter-over-quarter to 87.40%. James Simons is noted as the largest institutional shareholder, though other significant holders like PRIMECAP Management Company and Morgan Stanley & Co. LLC are also listed with their respective shareholdings and changes.
Pulmonx Corp (LUNG) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Pulmonx Corp (LUNG), highlighting its current earnings forecast score, average price target of $4.50, and analyst ratings. Based on 5 analysts, the stock has a "Buy" trend. The article also includes expected revenue and EPS for upcoming quarters and compares LUNG to its peers in the Healthcare Equipment & Supplies industry.
Pulmonx Corp (LUNG) Valuation: PE, PB & Fair Value Analysis
The article provides a valuation analysis for Pulmonx Corp (LUNG), noting its current valuation score is 7.71, ranking 137 out of 204 in the Healthcare Equipment & Supplies industry. It highlights the company's P/E ratio of -0.97, which represents a decrease from its recent high and an increase from its recent low. The analysis indicates that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Pulmonx Corp (LUNG) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Pulmonx Corp's (LUNG) dividend and stock split history, noting that no dividend data or stock split data is available. It shows the current stock price, market cap, and links to various company and market analysis sections on the TradingKey platform.
Pulmonx Corp (LUNG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Pulmonx Corp (LUNG), detailing its revenue by geographical region for the fiscal year 2023. The United States contributed the largest portion of revenue at 63.01% ($57.02 million), followed by Europe, Middle-East and Africa ("EMEA") and Asia Pacific. The company has not yet disclosed relevant data for business segment revenue.
[Form 4] Pulmonx Corp Insider Trading Activity
Pulmonx Corp director Thomas William Burns has been granted 40,000 Restricted Stock Units (RSUs) as compensation, not through a market purchase. These RSUs, valued at $0.0000 per share, will vest on the earlier of one year from the June 5, 2026 grant date or the date of the Annual Meeting of Stockholders for the subsequent year. Following this grant, Burns directly holds 113,399 shares of Pulmonx common stock.
Pulmonx (LUNG) director receives 40,000-share RSU stock grant
Pulmonx Corp director Dana G. Mead Jr. was granted 40,000 Restricted Stock Units (RSUs) which are payable in common stock. This is an equity compensation award, not an open-market purchase, with a grant price of $0.00 per share. These RSUs will vest on the earlier of June 5, 2026, or the company’s next annual stockholder meeting, increasing Mead's direct holdings to 139,714 Pulmonx shares, plus 4,076 shares held indirectly through The Mead Family Trust.
[Form 4] Pulmonx Corp Insider Trading Activity
Pulmonx Corp director Florin Daniel P was granted 40,000 Restricted Stock Units (RSUs) on June 5, 2026, as reported in a Form 4 filing. This RSU grant, which has a price per share of $0.00, increases his direct holdings to 133,910 shares. The RSUs are set to vest on the earlier of the one-year anniversary of the grant date or the company's next annual stockholder meeting.
LUNG SEC Filings - Pulmonx Corp 10-K, 10-Q, 8-K Forms
This page provides access to SEC filings for Pulmonx Corporation (LUNG), a medical technology company. It includes 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider trading forms. The filings detail the company's financial results, governance, compensation, and capital structure, with the most recent filing dated August 1, 2025.
[Form 4] Pulmonx Corp Insider Trading Activity
This article reports an insider trading activity for Pulmonx Corp (LUNG), detailing a single transaction by director Richard Ferrari. The transaction involved the acquisition of 40,000 shares of common stock through a Restricted Stock Units grant, bringing his total direct holdings to 127,024 shares. The report includes the full SEC Form 4 filing which specifies the conditions of the RSU grant.
Don't Ignore The Insider Selling In Pulmonx
Pulmonx Corporation's CEO and President, Glendon French, recently sold US$87k worth of stock at US$1.55 per share, following an earlier sale of US$97k below the current price. Insiders own 5.1% of Pulmonx shares, worth approximately US$3.3m, but there have been no insider purchases in the last year, only sales. This continuous insider selling and relatively low insider ownership raise concerns about the stock's future prospects.
Pulmonx (LUNG) officer sells 14,497 shares to cover RSU tax withholding
Pulmonx Corp's Chief Science & Technology Officer, Radhakrishnan Srikanth, sold 14,497 shares of common stock on June 1, 2026, across four transactions at $1.54 per share. These sales totaling $22,325 were made exclusively to cover tax withholding obligations stemming from the vesting of Restricted Stock Units granted between 2023 and 2026. This activity is considered a routine, tax-related insider transaction rather than a discretionary sale.
Pulmonx general counsel David Lehman sells $22,474 in stock
David Aaron Lehman, General Counsel at Pulmonx Corp, sold 14,594 shares of company stock worth $22,474 on June 1, 2026, to cover tax obligations from vested RSUs. This transaction occurred as Pulmonx faces financial challenges, including quickly burning through cash and remaining unprofitable, despite exceeding EPS expectations in Q1 2026 but missing revenue forecasts. Lehman still holds 376,161 shares of Pulmonx common stock.
Pulmonx general counsel David Lehman sells $22,474 in stock
Pulmonx general counsel David Lehman sold $22,474 worth of company stock to cover tax withholding obligations related to RSU vesting. This sale involved 14,594 shares at $1.54 each, aligning with the company's declining stock price. Pulmonx recently reported mixed Q1 2026 financial results, with better-than-expected EPS but a revenue miss, and InvestingPro tips indicate the company is burning cash and remains unprofitable.
Pulmonx (LUNG) CCO sells shares to cover RSU tax obligations
Pulmonx Corp's Chief Commercial Officer, Geoffrey Beran Rose, sold 8,023 shares of common stock at $1.54 per share on June 1, 2026. These sales were conducted to cover tax withholding obligations associated with the vesting of his Restricted Stock Units from 2023, 2024, 2025, and 2026. After these transactions, Rose still holds a substantial 463,956 shares, indicating that these were routine tax-related dispositions rather than a significant reduction of his stake in the company.
Pulmonx (LUNG) General Counsel sells 14,594 shares to cover RSU tax obligations
Pulmonx Corp General Counsel David Aaron Lehman sold 14,594 shares of common stock at $1.54 per share on June 1, 2026. These sales were executed in four transactions solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted between 2023 and 2026. This activity is compensation- and tax-related, not a discretionary reduction in his investment.
Pulmonx (LUNG) CEO logs 56K-share sale tied to RSU tax withholding
Pulmonx Corp CEO Glendon E. French III sold 56,149 shares of common stock on June 1-2, 2026, at prices between $1.54 and $1.57 per share. These sales were made to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs) granted on March 1, 2023, and are not considered discretionary trades. Following these transactions, French directly holds 1,178,162 shares and indirectly holds 918,198 shares through a family trust.
17 Pulmonx hires receive 84,300 RSUs in Nasdaq inducement plan
Pulmonx (Nasdaq:LUNG) has granted equity awards totaling 84,300 Restricted Stock Units (RSUs) to 17 new employees hired in the first two quarters of 2026. These awards, issued under its 2025 Inducement Plan, are subject to a four-year vesting schedule, with one-fourth vesting on the one-year anniversary of the June 1, 2026 Grant Date, and the remainder vesting quarterly over the subsequent three years. This initiative aims to attract and retain talent in compliance with Nasdaq Listing Rule 5635(c)(4).
Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulmonx Corporation announced that it granted equity awards to 17 new employees on June 1, 2026, under its 2025 Inducement Plan. These awards, totaling 84,300 restricted stock units, were approved by the Compensation Committee as an inducement for employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, contingent on continuous employment.
LUNG - Pulmonx Corp Stock Price and Quote
This article provides a detailed stock quote and financial data for Pulmonx Corp (LUNG), including its latest closing price, market capitalization, income, sales, and various financial ratios. It also lists recent analyst ratings and a chronology of news and earnings reports related to the company, alongside insider transaction data.
Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulmonx Corporation announced equity grants under its 2025 Inducement Plan to 17 new employees hired in the first two quarters of 2026. These inducement awards, totaling 84,300 restricted stock units (RSUs), were approved by the Compensation Committee and are subject to vesting schedules contingent on continuous employment. The grants are in accordance with Nasdaq Listing Rule 5635(c)(4).
Pulmonx Corp stock (US74586W1018): Q1 2026 results highlight growth path in minimally invasive lung treatments
Pulmonx Corp reported its Q1 2026 results, detailing the progress and demand for its Zephyr endobronchial valve therapy for severe COPD and emphysema. The company's revenue is driven by the sales of these valves and associated tools, emphasizing physician adoption, reimbursement frameworks, and expanding treatment centers. Despite being a smaller-cap medical device company, Pulmonx focuses on minimally invasive treatments and its market capitalization is around $56.59 million, reflecting its niche but growing position in interventional pulmonology.
Pulmonx Corp stock (US74586W1018): credit line and margin focus keep lung care specialist in the spotlight
Pulmonx Corp, a minimally invasive lung treatment specialist, is navigating a growth pause by focusing on margin improvement and strengthened liquidity. The company secured a new $60 million interest-only credit facility and ended the quarter with $61.6 million in cash equivalents. This financial flexibility, alongside disciplined cost control and continued investment in physician education, is crucial as Pulmonx works to reaccelerate growth for its Zephyr valve system, which treats severe emphysema.
Pulmonx Corp 1Q 2026: Revenue $20.59M, EPS ($0.33) — 10-Q Summary
Pulmonx Corp reported its first-quarter 2026 results, showing a decline in revenue to $20.59 million from $22.54 million year-over-year. The company posted a net loss of ($13.65 million) or ($0.33) per diluted share. Key factors included lower unit sales and lost China shipments, though the company continues to see positive commercial momentum with reimbursement gains and is investing in product development.
Pulmonx (NASDAQ: LUNG) secures $40M Perceptive loan and ends Q1 with $61.6M cash
Pulmonx (NASDAQ: LUNG) reported Q1 2026 results including $20.6 million in revenue, a net loss of $13.7 million, and an improved gross margin of 77.9%. The company secured a new $40 million senior secured term loan from Perceptive Credit Holdings V, LP, replacing a prior facility, and ended the quarter with $61.6 million in cash and equivalents. Pulmonx continues to invest in research and development and sales and marketing, expecting ongoing operating losses.
Pulmonx Corporation (NASDAQ:LUNG) Receives Consensus Recommendation of "Hold" from Analysts
Pulmonx Corporation (NASDAQ:LUNG) has received a consensus "Hold" rating from analysts, with an average one-year price target of $5.38, significantly above its current trading price of around $1.35. The company remains unprofitable, reporting a Q1 EPS of $(0.33) and negative net margin and ROE, with analysts forecasting a full-year EPS of -$1.12. Despite insider selling, institutional ownership is high, with some major firms recently increasing their stakes.
Pulmonx (NASDAQ:LUNG) Downgraded to "Sell" Rating by Wall Street Zen
Pulmonx (NASDAQ:LUNG) was downgraded to a "sell" rating by Wall Street Zen. Despite this, the consensus rating from other analysts remains "Hold" with an average target price of $5.38. The company is currently unprofitable, and its CEO recently sold a significant number of shares, although institutional ownership is high.
Pulmonx Corporation (NASDAQ:LUNG) Q1 2026 Earnings Call Transcript
Pulmonx Corporation reported Q1 2026 revenue of $20.6 million, a 9% decrease from the prior year, but reiterated its full-year 2026 revenue guidance of $90 million to $92 million. The company is focused on reaccelerating U.S. sales growth, advancing its AeriSeal program, and aligning cost structure, expecting a return to double-digit growth in the second half of 2026. Despite a temporary halt in sales to China due to pending registration renewal, other international markets showed solid growth.
Pulmonx Corp expected to post a loss of 33 cents a share - Earnings Preview
Pulmonx Corp (LUNG) is projected to report a loss of 33 cents per share, according to this earnings preview. The information was sourced from Refinitiv and suggests an upcoming financial announcement for the company.
Is Pulmonx (LUNG) 85.3% Undervalued After Q1 2026 Beats? EPS -$0
Pulmonx Corp (LUNG) reported its Q1 2026 results, surpassing revenue and EPS estimates with $20.6 million in revenue and a GAAP EPS of -$0.33. Despite a 9% year-over-year revenue decline, the company saw gross margin expand to 78% and attributed international declines to a temporary registration pause in China. GuruFocus considers LUNG 85.3% undervalued, trading at a significant discount to its intrinsic value.
Pulmonx (LUNG) Projects 2026 Revenue Between $90M and $92M
Pulmonx Corp (LUNG) has reaffirmed its 2026 revenue guidance, projecting between $90 million and $92 million, with a robust gross margin near 75%. Despite anticipated operating expenses between $113 million and $115 million, the company, which specializes in minimally invasive treatments for severe emphysema, shows strength in growth but has concerns regarding profitability and financial stability. Its GF Score™ of 59 and a low price-to-sales ratio of 0.55 suggest potential undervaluation, though caution is advised due to insider selling and financial health indicators.
Pulmonx Corporation (LUNG) Stock Falls on Q1 2026 Earnings
Pulmonx Corporation (LUNG) reported Q1 2026 results with total revenue down 8.7% year-over-year and slightly below consensus estimates, causing its stock to fall 1.71%. The company also saw a decrease in gross profit and net income, alongside significant insider selling activity and mixed institutional investor movements.
Earnings call transcript: Pulmonx Q1 2026 reveals mixed results, stock dips
Pulmonx (LUNG) reported mixed financial results for Q1 2026, with an EPS of -$0.33, beating estimates, but revenue of $20.6 million, missing forecasts. The stock dropped 0.81% in aftermarket trading, nearing its 52-week low, due to investor concerns over the revenue miss and continued net losses. Despite the challenges, the company is focused on re-accelerating U.S. sales, advancing its AeriSeal program to expand its market, and aligning its cost structure for profitability, with management expressing confidence in returning to double-digit growth by year-end.
Pulmonx (NASDAQ: LUNG) Q1 revenue falls 9% but 2026 outlook reaffirmed
Pulmonx Corporation reported a 9% decrease in Q1 2026 revenue to $20.6 million, largely due to a lack of sales into China. Despite the revenue fall, the company improved gross margins to 78% and narrowed its net loss, reaffirming its full-year 2026 revenue guidance of $90–$92 million. Management highlighted refreshed U.S. commercial strategies and a fully staffed global sales organization to drive future growth.
No China sales cut Pulmonx revenue 9%, but 2026 forecast holds
Pulmonx (Nasdaq: LUNG) reported a 9% year-over-year revenue decrease in Q1 2026 to $20.6 million, primarily due to the absence of sales in China, though ex-China international revenue rose by 22%. Despite the revenue decline, the company saw improved gross margin at 78% and a reduced net loss, and reaffirmed its full-year 2026 revenue guidance of $90 million to $92 million. Pulmonx also refinanced its debt with a new 5-year interest-only credit facility extending maturity to 2031, providing financial flexibility.
Pulmonx Reports First Quarter 2026 Financial Results
Pulmonx Corporation reported its financial results for the first quarter of 2026, with worldwide revenue reaching $20.6 million, a 9% decrease year-over-year. The company affirmed its full-year 2026 revenue guidance of $90 million to $92 million and expects to achieve sequential improvements in revenue growth.
Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference
Pulmonx Corporation, a leader in minimally invasive treatments for severe lung disease, has announced it will present at the Bank of America Securities 2026 Health Care Conference on May 12, 2026, in Las Vegas. A webcast of the presentation will be available on the Investors section of the company's website. Pulmonx focuses on devices like the Zephyr® Endobronchial Valve for patients with severe emphysema/COPD.
Pulmonx webcast set for May 12 Bank of America health conference
Pulmonx (Nasdaq: LUNG) will present at the Bank of America Securities 2026 Health Care Conference on Tuesday, May 12, 2026, at 8:15 AM PT / 11:15 AM ET. A live and archived webcast of the presentation will be available in the Investors section of the company's website. The announcement highlights Pulmonx's ongoing investor relations efforts, following recent positive news regarding earnings and a new credit facility, with the stock currently trading below its 52-week high.
Pulmonx (LUNG) Projected to Post Earnings on Wednesday
Pulmonx (NASDAQ:LUNG) is projected to release its Q1 2026 earnings after market close on Wednesday, April 29th, with analysts forecasting an EPS of ($0.33) and revenue of $20.431 million. The company reported better-than-expected EPS in the previous quarter and currently holds a "Hold" consensus rating from analysts with an average target price of $5.38. Insider selling, primarily by CEO Glendon E. French III, and high institutional ownership are also noted.
[ARS] Pulmonx Corp SEC Filing
This article announces an ARS SEC filing by Pulmonx Corp (LUNG) accepted on April 22, 2026. The filing has a low impact and neutral sentiment, and the full document is available in PDF format via SEC EDGAR. The article also provides a brief overview of Pulmonx Corp's stock and recent news and SEC filings.
Executive pay and board votes at Pulmonx (NASDAQ: LUNG) 2026 meeting
Pulmonx (NASDAQ: LUNG) will hold its virtual 2026 Annual Meeting on June 4, 2026, where shareholders will vote on electing three Class III directors, ratifying BDO USA, LLP as the independent auditor, and a non-binding advisory "say-on-pay" proposal for executive compensation. The company's executive compensation program emphasizes a mix of base salary, performance-based cash bonuses, and equity awards, including performance stock units, designed to align executive interests with long-term shareholder value. The 2025 bonus plan paid out 20.6% of target due to revenue falling below the threshold, while Adjusted EBITDA and limited strategic goals were partly achieved, and recent executive transitions for CEO Glendon French and COO/CFO Derrick Sung included performance-based equity grants.
How The Pulmonx (LUNG) Investment Narrative Is Resetting Around A Lower Target And Execution Risk
Pulmonx's investment narrative is re-centering around a lower US$5 price target, despite its fair value estimate remaining at US$5.17 per share. Bullish analysts view this as a more attainable goal, while bearish commentators see it as a sign of reduced near-term expectations and persistent execution risks. The company issued 2026 revenue guidance between US$90-US$92 million, with its intrinsic value model remaining largely unchanged.
